ADP-A2M4CD8,Nivolumab
adaptimmune therapeutics,bms
['surpass', 'adaptimmune']
on friday, adaptimmune presented the newest phase i surpass trial data for its mage-a4 cell therapy program. #esmo22 
The biopharma world is here. Get the industry’s most comprehensive daily news report at https://t.co/rXFyNyZcJs